I like reading the words of Dr Mark Lewis, an Oncologist and a Neuroendocrine Tumour (NET) patient himself (with MEN1). He always delivers with “enthusiastic vigour”, a term he reduces to “brio” (which I had to google!)
His article as usual sets a scene and he has form for looking back in the history of NETs. I’m sure he does this as it can often illustrate just how much clinical progress has been made since way back then. And that is the purpose of the recent article entitled “Continuing the Odyssey in the Land of Small Tumors“. He quotes from a 1987 article written by Dr Charles Moertel entitled “An Odyssey in the Land of Small Tumors” and I suspect he selected this article from Dr Moertel as he too writes with “brio”.
“Patients present in an almost surrealistic manner – a mix of tumor-related symptoms and signs, with bizarre and sometimes grotesque endocrine syndromes”
The article from 1987, when somatostatin analogues were starting to be used, must have been a hugely exciting time, perhaps more so than when peptide receptor radiotherapy (PRRT) became a thing in the 21st Century. After setting the scene using Dr Moeortel’s work, Dr Lewis then introduces a recent paper by well-known NET Specialist Dr Pamela Kunz and Dr Janie Zhang, a Hematology/Oncology Fellow at Yale-New Haven Hospital. Dr Lewis introduces their work with “After more than three decades of interim research, the article in this issue by Zhang and Kunz provides a contemporary framework for approaching the titular small tumors, with updates on nomenclature, diagnostic workup, and management“. Please note this review will focus on tumor control in NETs (i.e. not in Neuroendocrine Carcinomas).
In his own paper, Dr Lewis quite rightly points out the continued confusion whereby the classification of neuroendocrine tumors (NETs) has long been obfuscated by the etymology of the German word karzinoide, a misnomer if it is translated to mean that this cancer-like disease is uniformly benign. Clearly there’s still a lot of work to do to get rid of that obfuscation, the thoracic guys are still behind the curve.
As a patient himself, Dr Lewis also covers the issue of patient quality of life. Clearly there’s a balance required making therapy decisions often tough for the physician and patient, particularly when the therapy may be different across the broad spectrum of NET types and primary locations. Another area where many unmet needs still remain.
And he approaches the tricky subject of therapy sequencing with the words “This risk-benefit calculus is crucial in caring for patients whose longevity can be measured in years, if not decades, and for whom therapeutic options have multiplied to the point that the sequence of their use must be considered“. Working out the best sequencing is difficult, particularly with so many factors involved not least the different types of NET and primary locations. This is really a work in progress and perhaps will always be.
Both papers make for excellent reads and summaries of just how far we’ve come. Clearly there’s still a long way to go! I encourage you to read both recently published papers in this sequence:
1. Continuing the Odyssey in the Land of Small Tumors, Mark A. Lewis, MD, DOI: 10.1200/OP.21.00598 JCO Oncology Practice, published online October 15, 2021, PMID: 34652964 (click here)
2. Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors, 34652954 (click here), DOI: 10.1200/OP.21.00240 JCO Oncology Practice, Published online October 15, 2021, PMID:
And for those who, like Dr Mark Lewis and myself, like reading articles with “memorable brio”, you may also enjoy the 1987 work from Dr Moertel:
Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5:1502–1522, 1987 Click this Link
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like this page.
I’m also active on this Facebook page. Follow this page.
Also like this awareness page on Facebook.
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
A spotlight on Chromogranin A
What is Chromogranin A? Chromogranin A (CgA) is an acidic protein released along with catecholamines from chromaffin cells and nerve terminals. This statement alone might
Neuroendocrine Cancer: Catch them early, not late!
Diagnosing Neuroendocrine Neoplasms (NENs). It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can
A spotlight on Rectal Neuroendocrine Neoplasms
What are Rectal NENs Rectal Neuroendocrine Neoplasms (NENs) (rNENs) account for approximately 1-2% of all primary cancers in the rectum. The other main cancer types
Clinical Trial: Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)
A new clinical trial post. What is Terbium-161 (161Tb-DOTA-LM3) (Beta plus). Terbium-161 is a radioactive substance. DOTA-LM3 is a novel somatostatin antagonist targeted using somatostatin
Repeat after me: Maria Menounos has Neuroendocrine Cancer
Like many people from outside USA, I don’t really know anything about Maria Menounos. For those in the same boat, let me confirm she is
Summary of April 2023 on RonnyAllan.NET
Summary of RonnyAllan.NET website activity in April 2023 The top 10 most read posts in April are included below as the main product of this summary
A spotlight on 5-HIAA
Background. It’s important to note that not every type of Neuroendocrine Neoplasm will get the same tests due to the heterogenous nature of this cancer type.
The NET Detectives
The NET Detectives is an awareness post. Detecting NETs In general, it’s probably true to say that Neuroendocrine Tumours (NETs) are difficult to diagnose. Some
Low FODMAPs – The NET Effect
Background Many people with NET have had issues prior to diagnosis and then continue to have similar issues after. For some it will be either